Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease

Summary

Three quarters of patients with Alzheimer's disease have at least one vascular risk factor (VRF). Vascular brain lesions are present in most Alzheimer's patients (especially older ones). This cerebrovascular disease potentiates Alzheimer's lesions in early-stage disease. Many research studies have shown that VRFs are also risk factors for Alzheimer's disease; this is true for arterial hypertension and dyslipidaemia in particular and, to a lesser extent, diabetes and cardiopathy. Moreover, recent drug trials (SYST-EUR, PROGRESS and HOPE) have indicated that antihypertensive medications can prevent the appearance of dementia (and notably Alzheimer's disease) in over-60 hypertensive subjects. An observational study of 233 Alzheimer's patients with an average follow-up period of 4 years has shown that the annual decline in the Mini-Mental State Examination (MMSE) score was lower in patients in whom all the VRFs were being treated than in patients in whom no VRFs were being treated (1.5 ± 2.5 points versus 2.5 ± 2 points, respectively; p\<0.04).1 However, it is not currently known whether optimal treatment of VRFs can influence the progression and prognosis of Alzheimer's disease. Answering this question could have a significant impact on public health.

Conditions

• Alzheimer's Disease
• Cardiovascular Risk Factors

Interventions

OTHER

optimal care of VRF

VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.

OTHER

standard care

AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines

Sponsors & Collaborators

• Ministry of Health, France

  collaborator OTHER_GOV

• University Hospital, Lille

  lead OTHER

Principal Investigators

• Florence PASQUIER, MD · Univ Lille Nord de France, clinique neurologique, Centre Mémoire de Ressources et de Recherche - CHRU Lille

• Marie-Anne MACKOWIAK, MD · Univ Lille Nord de France, clinique neurologique, Centre Mémoire de Ressources et de Recherche - CHRU Lille

• Didier HANNEQUIN, MD · CHU Rouen

• Olivier GODEFROY, MD · CHU Amiens

• Muriel RAINFRAY, MD · University Hospital, Bordeaux

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-03-15

Primary Completion

2022-05-31

Completion

2022-05-31

Countries

• France

Study Locations